{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T08:42:39Z","timestamp":1696322559800},"reference-count":19,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,7,4]],"date-time":"2017-07-04T00:00:00Z","timestamp":1499126400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec><jats:title>Hintergrund<\/jats:title><jats:p>In der letzten Zeit wurden in der Literatur vermehrt erh\u00f6hte Hauttoxizit\u00e4ten w\u00e4hrend einer Kombinationstherapie mit BRAF Inhibitoren und Radiotherapie beschrieben.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material und Methodik<\/jats:title><jats:p>Wir berichten \u00fcber sieben Melanompatienten in einem nicht resezierbaren Stadium\u00a0III oder IV, die eine kombinierte Behandlung aus Bestrahlung und BRAF\u2010Inhibitor erhielten.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ergebnisse<\/jats:title><jats:p>Bei allen Patienten konnte durch die Kombinationstherapie ein gutes lokales Ansprechen erreicht werden. Nur bei zwei Patienten wurde eine schwere Radiodermatitis (CTCAE Grad\u00a03 bzw. 4) beobachtet. Bei diesen Patienten, die beide Vemurafenib erhielten, trat die Radiodermatitis nach ein bzw. zwei Wochen auf und resultierte in einer Unterbrechung der BRAF\u2010Inhibitor Behandlung.. Die kumulative Dosis bis zum Zeitpunkt der Strahlendermatitis betrug 10\u00a0Gy bzw. 35\u00a0Gy. Bei allen anderen Vemurafenibpatienten konnten nur milde Reaktionen im Sinne einer Radiodermatitis CTCAE Grad\u00a02, beim Dabrafenibpatienten CTCAE Grade\u00a01 diagnostiziert werden. Bei einem Patienten wurde eine Recalldermatitis nach 14 Tagen einer beendeten Strahlentherapie mit einer kumulativen Dosis von 30\u00a0Gy diagnostiziert.<\/jats:p><\/jats:sec><jats:sec><jats:title>Schlussfolgerungen<\/jats:title><jats:p>Schwere Toxizit\u00e4tsreaktionen der Haut unter einer BRAF\u2010Inhibitionen treten nicht h\u00e4ufig auf und sind meistens gut therapierbar. Deshalb sollte die Kombinationstherapie bei aggressiv wachsenden Melanomen eine Therapieoption bleiben. Obwohl ein erh\u00f6htes Risiko der Hauttoxizit\u00e4t unter einer Kombinationstherapie von Radiatio und BRAF\u2010Inhibitoren besteht, wird diese von den meisten Patienten gut toleriert. Sequenzielle Therapie anstelle von gleichzeitiger Behandlung scheint die Toxizit\u00e4treaktionen nicht zu verhindern.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ddg.12672_g","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T03:25:16Z","timestamp":1499225116000},"page":"703-708","source":"Crossref","is-referenced-by-count":0,"title":["Radiosensibilisierung durch BRAF Inhibitoren"],"prefix":"10.1111","volume":"15","author":[{"given":"Sophia Boyoung","family":"Strobel","sequence":"first","affiliation":[{"name":"Abteilung f\u00fcr Dermatologie und Nationales Centrum f\u00fcr Tumorerkrankungen, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"P\u00e4tzold","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Dermatologie, Universit\u00e4tsklinikum Frankfurt, Frankfurt, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Dermatologie, Universit\u00e4tsklinikum, Universit\u00e4t Duisburg\u2010Essen, Essen, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Jensen","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Radioonkologie, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Enk","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Dermatologie und Nationales Centrum f\u00fcr Tumorerkrankungen, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica Cecile","family":"Hassel","sequence":"additional","affiliation":[{"name":"Abteilung f\u00fcr Dermatologie und Nationales Centrum f\u00fcr Tumorerkrankungen, Universit\u00e4tsklinikum Heidelberg, Heidelberg, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,7,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103782"},{"issue":"6","key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ddg.12044","article-title":"Malignant melanoma S3\u2010guideline \u201cdiagnosis, therapy and follow\u2010up of melanoma","volume":"11","author":"Pflugfelder A","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"issue":"7","key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1610-0387.2012.07942.x","article-title":"Side effects of systemic oncological therapies in dermatology","volume":"10","author":"Zimmer L","year":"2012","journal-title":"J Dtsch \u00adDermatol Ges"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0063-4"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4265"},{"key":"e_1_2_6_7_1","article-title":"Acute radiation skin toxicity associated with BRAF inhibitors","author":"Pulvirenti T","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.4200"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7755"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.8473"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4389"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds292"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1113752"},{"issue":"4","key":"e_1_2_6_14_1","first-page":"297","article-title":"Vemurafenib: an unusual UVA\u2010induced photosensitivity","volume":"22","author":"Gelot P","year":"2013","journal-title":"ExpDermatol"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2010.12.017"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-014-0707-0"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-014-0698-x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000078"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70138-9"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9098(199708)65:4<284::AID-JSO11>3.0.CO;2-2"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.12672_g","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.12672_g","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T10:25:16Z","timestamp":1696242316000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.12672_g"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1111\/ddg.12672_g"],"URL":"https:\/\/doi.org\/10.1111\/ddg.12672_g","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}